Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Reports Strong Q1 2026 Results with Revenue and EPS Growth
Summary
Thermo Fisher Scientific Inc. reported its financial results for the first quarter of 2026, showing a 6% increase in revenue to $11.01 billion and a 11% increase in GAAP diluted EPS to $4.43. The company also announced strategic collaborations with NVIDIA and SHL Medical, the acquisition of Clario, and a $3.0 billion stock repurchase program. Organic revenue growth was 1%, and adjusted EPS grew 6% to $5.44. The company's business segments, including Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services, all contributed to the overall growth.
Profitelligence Alerts
Get alerts for TMO
Be first to know when Thermo Fisher Scientific Inc. files with the SEC.
Filing Categories
Advertisement
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. is a world-leading biotechnology company that provides essential tools and services for life sciences, biotechnology, pharmaceutical, and healthcare industries. Renowned for its extensive portfolio, the company specializes in offering innovative laboratory products, analytical instruments, and software solutions critical for research, diagnostics, and clinical applications. Thermo Fisher enables scientists to perform complex experiments with cutting-edge technology, from DNA sequencing and cell analysis to clinical diagnostics and specialty chemicals. Serving a vast array of sectors, the company impacts fields such as diagnostics, genetic engineering, and environmental monitoring. Its strategic acquisitions and collaborations strengthen its market presence, making it a go-to partner for scientific advancements and innovation. With operations spanning over 50 countries, Thermo Fisher plays a pivotal role in driving scientific discovery and improving health outcomes globally.
Official SEC Documents
Advertisement